| ST. JUDE CHILDREN'S RESEARCH HOSPITAL INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20130095114 | T Cell Regulation - Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies. | 04-18-2013 |
| 20120282256 | CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN - The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the | 11-08-2012 |
| 20120178087 | Genotyping Assay to Predict Gamma Glutamyl Hydrolase (GGH) Activity - Single nucleotide polymorphisms (SNPs) in the gene encoding gamma glutamyl hydrolase (GGH) associated with reduced GGH activity are disclosed. The primary SNP is a change from a cytosine to a thymine at a position corresponding to nucleotide 511 of Genbank sequence accession no. NM 003878. Methods and kits for detecting these SNPs are provided, along with primers useful in detecting these SNP and for amplifying portions of the GGH gene containing these SNPs. | 07-12-2012 |
| 20100196394 | ANTI-CANCER VACCINE COMPOSITION - Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies. | 08-05-2010 |
